PSB-10

Source: Wikipedia, the free encyclopedia.
PSB-10
Clinical data
Other namesPSB-10
Identifiers
  • (8R)-ethyl-4-methyl-2-(2,3,5-trichlorophenyl)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one
JSmol)
  • Clc2cc(Cl)cc(c2Cl)C(=N3)NC1C3N(C)C(=O)N4C1=NC(C4)CC
  • InChI=1S/C16H14Cl3N5O/c1-3-8-6-24-15(20-8)12-14(23(2)16(24)25)22-13(21-12)9-4-7(17)5-10(18)11(9)19/h4-5,8H,3,6H2,1-2H3,(H,21,22)/t8-/m1/s1 ☒N
  • Key:YYDHUJWLNPIBDS-MRVPVSSYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

PSB-10 is a drug which acts as a selective

DPCPX have generally low affinity for the A3 subtype and must be extended by expanding the ring system and adding an aromatic group to give high A3 affinity and selectivity.[3] The affinity towards adenosine A3 subtype was measured against the radioligand PSB-11.[4]

References

  1. PMID 12517430
    .
  2. S2CID 6110998
    .
  3. PMID 12570761. Archived from the original
    on April 14, 2013. Retrieved April 28, 2020.
  4. PMID 11814828
    .
drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=PSB-10&oldid=1203023165"
This page is based on the copyrighted Wikipedia article: PSB-10. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy